Treatments Compared for Pediatric-Onset Multiple Sclerosis
THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.
Patrick Vermersch, M.D., Ph.D., from the Centre Hospitalier Universitaire de Lille in France, and colleagues conducted an active-controlled, open-label randomized clinical trial involving patients with POMS aged 10 to <18 years. A total of 150 patients with POMS were randomly assigned to DMF or IFNβ-1a (78 and 72 individuals, respectively).
The researchers found that among the 103 trial completers, the proportion of patients with no N or NE T2 hyperintense lesions at week 96 was 16.1 and 4.9 percent for DMF and IFNβ-1a, respectively; in a sensitivity analysis among the intention-to-treat population, the proportions were 12.8 and 2.8 percent, respectively. The estimated proportion of patients who remained relapse-free was 66.2 and 52.3 percent for DMF and IFNβ-1a, respectively, at week 96. The adjusted annualized relapse rate was 0.24 and 0.53 for DMF and IFNβ-1a, respectively, at week 96; the rate ratio was 0.46 for DMF versus IFNβ-1a.
"The CONNECT randomized clinical trial found that DMF led to meaningful improvements in radiological and clinical outcomes in patients with POMS, with a positive benefit-risk balance," the authors write.
Several authors disclosed financial ties to biopharmaceutical companies, including Biogen, which manufactures dimethyl fumarate and funded the trial.
Related Posts
988 Mental Health Hotline Back in Business After Daylong Outage
FRIDAY, Dec. 2, 2022 (HealthDay News) -- A national hotline that people can call...
Rural Residence Tied to Higher Risk for Heart Failure for Women, Black Men
FRIDAY, Jan. 27, 2023 (HealthDay News) -- Rural residence is associated with an...
Having Kids Around Might Shield You From Severe COVID: Study
MONDAY, Aug. 1, 2022 (HealthDay News) -- Folks with young kids at home may be...
Consejos para mantenerse fresco en el calor extremo
SÁBADO, 10 de junio de 2023 (HealthDay News) -- El calor extremo puede ser...